Financial Summary

January 1, 2021 - December 31, 2021

Third Quarter

Second Quarter

First Quarter

January 1, 2020 - December 31, 2020

Fiscal Year

Third Quarter

Second Quarter

First Quarter

January 1, 2019 - December 31, 2019

Fiscal Year

Third Quarter

Second Quarter

First Quarter

IR Events

Update on KHK4083

October 4, 2021 (Material added on November 5, 2021)

This document is used only for the purpose of providing the information to investors. Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or medical advice.

Kyowa Kirin ESG Briefing

September 8, 2021

Joint Development and Commercial Agreement of KHK4083 with Amgen

June 1, 2021

R&D Day

December 10, 2020

Updates on Nourianz marketing strategy in the U.S. and KW-6356 development

November 19, 2019

Update on KHK4083: A phase 1 study in subjects with atopic dermatitis

December 3, 2018

Update on burosumab (KRN23): Clinical and regulatory updates, and pre-launch activities in the US and EU

October 27, 2017

IR Contents

2020 Sompo Sustainability index
2020 constituent MSCI Japan ESG select leaders index
2020 constituent MSCI Japan Empowering Women index
Daiwa Investor Relation 2019 Commendation Award
Gomez IR website ranking 2019 silver award